Ellen M. Zane serves as Independent Director of the Company. Ms. Zane is CEO Emeritus and Vice Chair of the board of trustees at Tufts Medical Center and Floating Hospital for Children, and previously, she served as its President and Chief Executive Officer. Ms. Zane also served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of nThrive, a Georgia-based private equity held company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; AgNovos Healthcare, LLC a privately held medical device company, focused on bone health; and Synchrony Financial, a public consumer financial services company. Ms. Zane previously served as a director of Century Capital Management, Parexel International Corporation, Lincare Holdings Inc., and Press Ganey Holdings. Ms. Zane holds a Professional Director Advanced Certification from the American College of Corporate Directors.
As the Independent Director of Boston Scientific, the total compensation of Ellen Zane at Boston Scientific is $299,979. There are 16 executives at Boston Scientific getting paid more, with Michael Mahoney having the highest compensation of $15,764,100.
Ellen Zane is 68, she's been the Independent Director of Boston Scientific since 2016. There are 1 older and 27 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.
Ellen's mailing address filed with the SEC is 777 LONG RIDGE ROAD, C/O SYNCHRONY FINANCIAL, STAMFORD, CT, 06902.
Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele et Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
Boston Scientific executives and other stock owners filed with the SEC include: